BioClin Therapeutics Adds Gilead’s Steve Abella to Executive Team

Esteban (Steve) Abella has been appointed chief medical officer of San Ramon, CA-based BioClin Therapeutics. Abella most recently worked at Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was a senior director leading the company’s non-Hodgkin lymphoma and leukemia efforts. BioClin also named Graeme Currie to the chief operating officer post. Currie’s experience includes senior leadership positions at Dynavax Technologies (NASDAQ: [[ticker:DVAX]]) and Regeneron Pharmaceuticals (NASDAQ: [[ticker:REGN]]).

BioClin’s lead drug candidate, B-701, targets a protein that supports tumor growth. Last year, BioClin raised $30 million in funding for more clinical studies testing the antibody drug as a treatment for bladder cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan